Laval Science Park Welcomes Corealis' Advanced Research Facilities

On June 10, 2024, Corealis Pharma celebrated the opening of its expanded facilities located in the centre of Laval's Biotech City. This expansion, funded by an investment of over $10 million, increases the size of the Quebec company's premises from 33,000 to 63,000 square feet, allowing for the addition of new cutting-edge laboratories

Yves Roy, President of Corealis, "My co-founders and I are immensely proud today to inaugurate these state-of-the-art laboratories. These facilities will bolster our research and development capabilities for new drugs, catering to global growth and enhancing our market presence.”

Founded in 2005 by scientists Yves Roy, Patrick Gosselin, and Yves Mouget, the company based in Laval quickly earned the confidence of small and medium-sized biotech firms worldwide, along with major pharmaceutical companies, establishing itself as a leading Contract Research and Development Organization (CRO/CDMO) globally.

In 2022, Corealis accelerated its growth by forming a partnership with the CDPQ and Archimed, a global investment firm specializing in healthcare industries. Serving clients primarily in New England and California, as well as in various other regions around the world, the company achieved a 20% increase in sales in 2023.

In addition to supporting workforce growth, the new facility will allow Corealis Pharma to accelerate the progress in the development and production of oral solid dosage forms, initiation and advancement of early-stage projects, development of analytical methods, adoption of cutting-edge analytical and formulation equipment and the speed scope of drug research and development.The company announced that opening its new facilities represents the fulfillment of a three-phase strategic plan designed to achieve its main goal: becoming the global standard in the development of oral solid dosage form formulations, thus strengthening Quebec's reputation as a biotechnology hub.